Ex­elix­is’ Cabome­tyx miss­es sur­vival end­point, but will still file in prostate can­cer

Ex­elix­is’ sec­ond-quar­ter earn­ings re­port re­vealed a pri­ma­ry end­point sta­tis­ti­cal sig­nif­i­cance fail­ure, a po­ten­tial mar­ket launch in­to a new in­di­ca­tion and an ADC cut.

De­spite Cabome­tyx …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER